Autonomix Medical, a leader in medical device innovation, has achieved a significant milestone with the issuance of U.S. patent 10,143,419 by the U.S. Patent and Trademark Office (USPTO). This patent, titled "Systems and Methods for Treating Cancer and/or Augmenting Organ Function," underscores the company's commitment to advancing cutting-edge technologies for diagnosing and treating nervous system disorders.

The patented technology represents a breakthrough in the interventional treatment of cancerous tumors and cancer-related pain. Autonomix's focus is initially directed towards alleviating pancreatic cancer-related pain, utilizing their catheter-based sensing technology. This groundbreaking approach enables precise detection of neural signals associated with pain or disease, facilitating targeted treatment of affected nerves.

By leveraging this innovative catheter-based sensing technology, Autonomix aims to revolutionize current approaches to pain management in cancer care. Unlike traditional methods reliant on opioids or blind interventions, Autonomix's solution offers enhanced precision and effectiveness, while minimizing the risk of side effects. This represents a significant step forward in improving the quality of life for cancer patients suffering from debilitating pain.

Source: globenewswire.com